Transforming Lives. Redefining Possibilities.

At Radiofilum Pharmaceutical , our purpose is to innovate to transform the lives of patients and their families.

We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.

We have a diverse portfolio of marketed medicines including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience.

Radiofilum Pharmaceutical is a global, diversified Pharmaceutical CDMO and biotechnology company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health. manufacture of drugs that treat rare and orphan diseases. Some of the drugs it has produced have been used to treat patients with symptoms related to central nervous system disorders, irregular heart conditions, immune system disorders, and cancer. One of the focuses of Radiofilum is treating individuals with pulmonary arterial hypertension (PAH), a heart condition that leaves patients with a short life expectancy (7–9 years) even with treatment.scientists were among the first to work in the field of endothelin receptor antagonists. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

We manufacture and market a broad range of branded and generic pharmaceuticals, and over-the-counter (OTC) products directly or indirectly in more than 90 countries and regions, including the United States, us, Europe, the Middle East, Africa, Asia Pacific and Latin America.

As a part of the renowned Group, the Contract Development and Manufacturing Organisation (CDMO) division offers comprehensive biopharmaceutical services. They specialize in the development and manufacturing of biologics, including monoclonal antibodies, recombinant proteins, and biosimilars. With a global presence and cutting-edge facilities, they provide end-to-end solutions from cell line development to commercial manufacturing.

As a small molecule partnership development and manufacturing organisation (PDMO), Radiofilum Pharmaceutical delivers comprehensive small molecule services spanning preclinical development to full commercial manufacturing. Widely recognised for our collaborative and transparent team, our expertise in complex and hazardous chemistries, and our service-focused customer experience, Radiofilum is a proven and trusted partner to the world’s most innovative biotechs and leading pharmaceutical companies.

Radiofilum has a 50+ year track record of providing a range of complementary services spanning the entire pharmaceutical lifecycle, from early stage discovery to full commercial roll-out. We are capable of supporting our customers’ projects from grammes to tonnes in-house, in a partnership-led service model that ensures full continuity every step of the way. Committed to innovation, we partner with leading academic and technological institutions, through our Technology and Innovation Programme, to apply emerging technologies in our customers’ programmes. Most importantly, we are dedicated to serving as true scientific partners to our customers, providing unrivalled service and support rooted in collaboration and transparency.

At Radiofilum, we pride ourselves on being easy to do business with, and we are focused on upholding a simple and collaborative way of working. We are so much more than a traditional CDMO. We are a PDMO, or partnership development and manufacturing organisation. Differentiated by the three core characteristics of service, passion, and science, we put our customers’ products first to transform the outsourcing experience.

Read more We have a diversified portfolio of products, which you can learn more about here.

As a part of the renowned Group,this segment offers help to pharmaceutical, biotechnology, and medical device companies bring life-changing therapies to market. From early development through clinical, regulatory approval, and commercialization, we provide expert guidance to navigate complex challenges and accelerate success.

Our mission in this division is simple - improving patient health and safety by delivering the highest quality regulatory, compliance, clinical research, pharmacovigilance, and medical information services throughout the entire product lifecycle.

Read more We have a diversified portfolio offer in the division which you can learn more about here.

The company is partnering global Innovative business segment.